OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
PALATINE, Ill., Aug. 03, 2017 -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for the second quarter 2017 following the close of financial markets on Monday, August 14, 2017. The Company will host a conference call to discuss the results on Tuesday, August 15, 2017 at 8:30 a.m. ET.
To participate in the live conference call, please dial 888-378-4398 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 167446.
A replay of the call will be available beginning August 15, 2017 and ending on September 15, 2017 on the company's website. The replay participant code is 6001822.
About Acura Pharmaceuticals
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITx™, AVERSION® and IMPEDE® Technologies. LIMITx contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.
OXAYDO® (oxycodone HCl immediate-release tablets) which incorporates the AVERSION Technology, is FDA approved and marketed in the U.S. by our partner Egalet Corporation.
NEXAFED® and NEXAFED® Sinus, which are pseudoephedrine containing products that utilize the IMPEDE Technology, are marketed in the U.S. by our partner MainPointe Pharmaceuticals LLC.
Contact: for Acura Investor Relations [email protected] 847-705-7709
